- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Reduction of elevated intraocular pressure or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 914KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 50KB)
Bimatoprost – July 2020
Bimatoprost: 300 micrograms per mL, 3 mL; Vizo-PF Bimatoprost®
Last updated
30 October 2020